Back to top

Analyst Blog

Acura Pharmaceuticals, Inc. (ACUR) entered into a settlement agreement with Impax Laboratories, Inc. (IPXL - Snapshot Report) and Par Pharmaceutical Companies, Inc. to resolve their patent litigation regarding Oxecta. Par was acquired by TPG Capital in 2012.

Oxecta is approved to manage the acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

With the litigation being settled, Par can now sell its generic version of Oxecta in the U.S. on Jan 1, 2022 or before under certain circumstances. Par’s launch of generic Oxecta depends on Acura’s grant of a non-exclusive, royalty-bearing license to Par. Par being the first Abbreviated New Drug Application filer for generic Oxecta is entitled to a 180-day exclusivity. Acura is entitled to get royalties of 10%–15% of Par's net profits from generic Oxecta sales.

As per the agreement, Impax can sell its generic version of Oxecta in the U.S. through the grant of a non-exclusive, royalty-free license from Acura. This will be effective 180 days after the first sale of a generic Oxecta in the U.S. or before under certain circumstances.

Meanwhile, other generic companies including Ranbaxy and Actavis Inc. (ACT - Analyst Report) are also seeking approval from the FDA to sell their generic version of Oxecta. Patent litigation against them is pending in the U.S. District Court. Acura has challenged the applications from these companies alleging infringement of U.S. patent no. 7,510,726, expiring in Nov 2023.

Acura currently carries a Zacks Rank #4 (Sell). Other companies that look well-positioned include Impax and Actelion Ltd. (ALIOF). While Actelion carries a Zacks Rank #1 (Strong Buy), Impax carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 26.62 +8.70%
CENTURY ALU… CENX 27.09 +8.53%
BANCO DO BR… BDORY 16.55 +6.57%
CANADIAN SO… CSIQ 37.50 +5.50%
TESLA MOTOR… TSLA 282.88 +5.07%